RÉSUMÉ
Neoplastic cells secrete autocrine motility factor (AMF) to stimulate the motility of cancer cells. In this study, AMF secreted from HT-29 colorectal cancer cells selectively suppressed liver cancer cells by downregulating pAKT and ß-catenin. In addition, HT-29 AMF significantly augmented the activity of methyl jasmonate against liver cancer cells and is a promising alternative for liver cancer therapy.
Sujet(s)
Acétates/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cyclopentanes/pharmacologie , Glucose 6-phosphate isomerase/pharmacologie , Tumeurs du foie/anatomopathologie , Oxylipines/pharmacologie , Acétates/administration et posologie , Cyclopentanes/administration et posologie , Régulation négative/effets des médicaments et des substances chimiques , Glucose 6-phosphate isomerase/administration et posologie , Cellules HT29 , Humains , Oxylipines/administration et posologie , Protéines proto-oncogènes c-akt/métabolisme , bêta-Caténine/métabolismeRÉSUMÉ
Autocrine motility factor (AMF) stimulates the motility of cancer cells via an autocrine route and has been implicated in tumor progression and metastasis. Overexpression of AMF is correlated with the aggressive nature of breast cancer and is negatively associated with clinical outcomes. In contrast, AMF also has the ability to suppress cancer cells. In this study, AMFs from different cancer cells were demonstrated to have suppressive activity against MCF-7 and MDA-MB-231 breast cancer cells. In a growth and colony formation assay, AMF from AsPC-1 pancreatic cancer cells (ASPC-1:AMF) was determined to be more suppressive compared to other AMFs. It was also demonstrated that AsPC-1:AMF could arrest breast cancer cells at the G0/G1 cell cycle phase. Quantified by Western blot analysis, AsPC-1:AMF lowered levels of the AMF receptor (AMFR) and G-protein-coupled estrogen receptor (GPER), concomitantly regulating the activation of the AKT and ERK signaling pathways. JAK/STAT activation was also decreased. These results were found in estrogen receptor (ER)-positive MCF-7 cells but not in triple-negative MDA-MB-231 cells, suggesting that AsPC-1:AMF could work through multiple pathways led to apoptosis. More importantly, AsPC-1:AMF and methyl jasmonate (MJ) cooperatively and synergistically acted against breast cancer cells. Thus, AMF alone or along with MJ may be a promising breast cancer treatment option.
Sujet(s)
Acétates/administration et posologie , Tumeurs du sein/traitement médicamenteux , Cyclopentanes/administration et posologie , Glucose 6-phosphate isomerase/administration et posologie , Oxylipines/administration et posologie , Antinéoplasiques d'origine végétale/administration et posologie , Protocoles de polychimiothérapie antinéoplasique , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Points de contrôle du cycle cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Clonage moléculaire , Cytokines/administration et posologie , Cytokines/génétique , Régulation négative/effets des médicaments et des substances chimiques , Synergie des médicaments , Femelle , Glucose 6-phosphate isomerase/génétique , Humains , Cellules MCF-7 , Thérapie moléculaire ciblée , Récepteur du facteur autocrine de motilité/métabolisme , Protéines recombinantes/administration et posologie , Protéines recombinantes/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Test clonogénique de cellules souches tumoralesRÉSUMÉ
Although regulatory T (Treg) cells are necessary to prevent autoimmune diseases, including arthritis, whether Treg cells can ameliorate established inflammatory disease is controversial. Using the glucose-6-phosphate isomerase (G6PI)-induced arthritis model in mice, we aimed to determine the therapeutic efficacy of increasing Treg cell number and function during chronic destructive arthritis. Chronic destructive arthritis was induced by transient depletion of Treg cells prior to immunization with G6PI. At different time points after disease induction, mice were treated with a CD28 superagonistic antibody (CD28SA). CD28SA treatment during the induction phase of arthritis ameliorated the acute signs of arthritis and completely prevented the development of chronic destructive arthritis. CD28SA treatment of mice with fully developed arthritis induced a significant reduction in clinical and histological signs of arthritis. When given during the chronic destructive phase of arthritis, 56 days after disease induction, CD28SA treatment resulted in a modest reduction of clinical signs of arthritis and a reduction in histopathological signs of joint inflammation. Our data show that increasing the number and activation of Treg cells by a CD28SA is therapeutically effective in experimental arthritis.
Sujet(s)
Anticorps monoclonaux/immunologie , Arthrite expérimentale/prévention et contrôle , Maladies auto-immunes/prévention et contrôle , Antigène CD28/immunologie , Lymphocytes T régulateurs/immunologie , Animaux , Anticorps monoclonaux/administration et posologie , Anticorps monoclonaux/usage thérapeutique , Maladies auto-immunes/immunologie , Antigène CD28/agonistes , Maladie chronique/prévention et contrôle , Modèles animaux de maladie humaine , Glucose 6-phosphate isomerase/administration et posologie , Inflammation/prévention et contrôle , Inflammation/thérapie , Articulations/immunologie , Articulations/physiopathologie , Souris , Lymphocytes auxiliaires Th1/immunologieRÉSUMÉ
Fingolimod (FTY720) is known to have a significant therapeutic effect in various autoimmune disease models. Here, we examined FTY720 in a model of rheumatoid arthritis, induced by immunizing DBA/1 mice with a peptide consisting of residues 325 through 339 of glucose-6-phosphate isomerase (GPI325-339). The efficacy was evaluated in terms of macroscopic findings, inflammatory cell infiltration and autoantibody level. Prophylactic administration of FTY720 from the day of immunization significantly suppressed the development of paw swelling, but therapeutic administration of FTY720 from onset of symptoms on day 8-9 was less effective. Interestingly, however, combination treatment with FTY720 plus GPI325-339 for 5 d after onset of symptoms significantly reduced the severity of symptoms in all mice, and no relapse occurred after booster immunization. Taking into account the reported mechanism of action of FTY720, these results indicate that combination treatment with FTY720 plus pathogenic autoantigen might efficiently induce immune tolerance by sequestering circulating autoantigen-specific lymphocytes from blood and peripheral tissues to the secondary lymphoid tissues. Combination treatment with FTY720 plus pathogenic autoantigen may become a breakthrough treatment for remission-induction in patients with autoimmune diseases including rheumatoid arthritis.
Sujet(s)
Polyarthrite rhumatoïde/traitement médicamenteux , Autoantigènes/administration et posologie , Glucose 6-phosphate isomerase/immunologie , Immunosuppresseurs/administration et posologie , Propylène glycols/administration et posologie , Sphingosine/analogues et dérivés , Animaux , Polyarthrite rhumatoïde/immunologie , Polyarthrite rhumatoïde/anatomopathologie , Autoanticorps/sang , Modèles animaux de maladie humaine , Association de médicaments , Chlorhydrate de fingolimod , Glucose 6-phosphate isomerase/administration et posologie , Glucose 6-phosphate isomerase/composition chimique , Immunoglobuline G/sang , Articulations/effets des médicaments et des substances chimiques , Articulations/anatomopathologie , Mâle , Souris , Souris de lignée DBA , Peptides , Sphingosine/administration et posologie , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Autocrine motility factor (AMF) is a multifunctional cytokine that promotes cellular adhesion, proliferation, motility, anti-apoptosis, and tissue repair. Direct nerve implantation (DNI) is considered to be effective in peripheral motor nerve injuries with disuse of the distal nerve; however, the repaired muscle function is not satisfactory. In our study, purified AMF was injected in reinnervated muscle after DNI with the intention of assessing if AMF, as a malignant tumor-related cytokine, could improve motor plate regeneration and neuromuscular function restoration. METHODS: Purified AMF, which was extracted from AMF-transfected myoblast-conditioned medium, was regularly injected into the rat gastrocnemius in an established rat gastrocnemius denervation and reinnervation model. The nerve conduction velocity (NCV) of the tibial nerve, peak-to-peak value (PPV), area under the curve (AUC) of the compound muscle action potential (CMAP) and the Tibial Functional Index (TFI) were measured at 8, 16 and 24 weeks after injection. The regenerated endplates in gastrocnemius were examined by histochemical staining. In another group, an AMF-free solution was injected as the control. RESULTS: After the AMF injection, the direct-nerve-implanted muscle function recovery was better in terms of both the nerve velocity and the quality. The endplates in the experimental group also had a quantitative advantage in restoration. After comparing the histochemical-stained tissues, no indications of tumorigenesis were detected. CONCLUSIONS: AMF had positive effects on neuromuscular reparation and need more detailed research to determine the signalling pathways and side effects of AMF.
Sujet(s)
Glucose 6-phosphate isomerase/pharmacologie , Muscles squelettiques/effets des médicaments et des substances chimiques , Régénération nerveuse/effets des médicaments et des substances chimiques , Animaux , Modèles animaux de maladie humaine , Glucose 6-phosphate isomerase/administration et posologie , Injections , Mâle , Dénervation musculaire/méthodes , Muscles squelettiques/innervation , Projets pilotes , Rats , Rat Sprague-Dawley , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Nerf tibial/effets des médicaments et des substances chimiques , Nerf tibial/traumatismesRÉSUMÉ
The absence of IFN-γ signaling leads to an increased inflammatory response in many murine models of autoimmune diseases induced by a CFA-assisted immunization schedule. We investigated the role of endogenous IFN-γ in arthritis induced by immunization with glucose-6-phosphate isomerase (G6PI) in CFA in DBA/1 mice. Surprisingly, and in contrast to our previous findings in collagen-induced arthritis (CIA), G6PI-induced arthritis was found to be reduced in IFN-γ receptor-deficient (IFN-γR KO) mice, demonstrating a proinflammatory role for IFN-γ in this model. Milder disease in IFN-γR KO mice was associated with less vigorous innate and adaptive immune responses early (day 9) after immunization: less proliferation of myeloid cells in the spleen, less osteoclast formation, less G6PI-reactive Th cells (as measured by ex vivo stimulation and flow cytometry and by in vivo skin reactivity to G6PI) and lower G6PI-specific immunoglobulin serum levels. Surprisingly, on day 21, despite continued milder disease in IFN-γR KO mice, their Th cell responses were no longer diminished but augmented as compared to wild-type mice, and their numbers of immature myeloid splenocytes were also more increased. These data reveal that IFN-γ signaling is critical for the induction of the early immune responses which trigger G6PI-induced arthritis. The strikingly different clinical consequences of absent IFN-γ signaling in G6PI-induced arthritis compared with the very similarly induced CIA emphasize that the role of a single cytokine in experimentally induced arthritis depends critically on the very nature of the inciting (auto)antigen and in particular on the kinetics of the disease manifestation elicited by the antigen.
Sujet(s)
Arthrite expérimentale/immunologie , Glucose 6-phosphate isomerase/immunologie , Interféron gamma/immunologie , Récepteur interféron/immunologie , Animaux , Arthrite expérimentale/génétique , Arthrite expérimentale/anatomopathologie , Lymphocytes B/immunologie , Lymphocytes B/métabolisme , Femelle , Cytométrie en flux , Prédisposition génétique à une maladie , Glucose 6-phosphate isomerase/administration et posologie , Immunité cellulaire/immunologie , Immunité innée/immunologie , Immunisation , Numération des lymphocytes , Mâle , Souris , Souris de lignée DBA , Souris knockout , Ostéoclastes/immunologie , Ostéoclastes/métabolisme , Récepteur interféron/déficit , Récepteur interféron/génétique , Lymphocytes T/immunologie , Lymphocytes T/métabolisme ,RÉSUMÉ
INTRODUCTION: Arthritis induced by immunisation with glucose-6-phosphate isomerase (GPI) in DBA/1 mice was proven to be T helper (Th) 17 dependent. We undertook this study to identify GPI-specific T cell epitopes in DBA/1 mice (H-2q) and investigate the mechanisms of arthritis generation. METHODS: For epitope mapping, the binding motif of the major histocompatibility complex (MHC) class II (I-Aq) from DBA/1 mice was identified from the amino acid sequence of T cell epitopes and candidate peptides of T cell epitopes in GPI-induced arthritis were synthesised. Human GPI-primed CD4+ T cells and antigen-presenting cells (APCs) were co-cultured with each synthetic peptide and the cytokine production was measured by ELISA to identify the major epitopes. Synthetic peptides were immunised in DBA/1 mice to investigate whether arthritis could be induced by peptides. After immunisation with the major epitope, anti-interleukin (IL) 17 monoclonal antibody (mAb) was injected to monitor arthritis score. To investigate the mechanisms of arthritis induced by a major epitope, cross-reactivity to mouse GPI peptide was analysed by flow cytometry and anti-GPI antibodies were measured by ELISA. Deposition of anti-GPI antibodies on the cartilage surface was detected by immunohistology. RESULTS: We selected 32 types of peptides as core sequences from the human GPI 558 amino acid sequence, which binds the binding motif, and synthesised 25 kinds of 20-mer peptides for screening, each containing the core sequence at its centre. By epitope mapping, human GPI325-339 was found to induce interferon (IFN) gamma and IL-17 production most prominently. Immunisation with human GPI325-339 could induce polyarthritis similar to arthritis induced by human GPI protein, and administration of anti-IL-17 mAb significantly ameliorated arthritis (p < 0.01). Th17 cells primed with human GPI325-339 cross-reacted with mouse GPI325-339, and led B cells to produce anti-mouse GPI antibodies, which were deposited on cartilage surface. CONCLUSIONS: Human GPI325-339 was identified as a major epitope in GPI-induced arthritis, and proved to have the potential to induce polyarthritis. Understanding the pathological mechanism of arthritis induced by an immune reaction to a single short peptide could help elucidate the pathogenic mechanisms of autoimmune arthritis.
Sujet(s)
Arthrite expérimentale/immunologie , Déterminants antigéniques des lymphocytes T/immunologie , Glucose 6-phosphate isomerase/toxicité , Séquence d'acides aminés , Animaux , Arthrite expérimentale/induit chimiquement , Arthrite expérimentale/enzymologie , Glucose 6-phosphate isomerase/administration et posologie , Humains , Souris , Souris de lignée DBA , Données de séquences moléculaires , Fragments peptidiques/synthèse chimique , Fragments peptidiques/immunologie , Liaison aux protéines/immunologieRÉSUMÉ
Antibodies specific for glucose-6-phosphate isomerase (G6PI) from T-cell receptor transgenic K/BxN mice are known to induce arthritis in mice, and immunization of DBA/1 mice with G6PI led to acute arthritis without permanent deformation of their joints. Because rheumatoid arthritis is a chronic disease, we set out to identify the capacity of G6PI to induce chronic arthritis in mice. Immunization with recombinant human G6PI induced a chronically active arthritis in mice with a C3H genomic background, whereas the DBA/1 background allowed only acute arthritis and the C57BL/10 background permitted no or very mild arthritis. The disease was associated with the major histocompatibility region sharing an allelic association similar to that of collagen-induced arthritis (i.e. q > p > r). All strains developed a strong antibody response to G6PI that correlated only in the C3H.NB strain with arthritis severity. Similarly, a weak response to type II collagen in a few mice was observed, which was associated with arthritis in C3H.NB mice. Mice on the C3H background also developed ankylosing spondylitis in the vertebrae of the tail. Both C3H.Q and B10.Q mice deficient for B cells were resistant to arthritis. We conclude that G6PI has the ability to induce a chronic arthritis, which is MHC associated and B-cell dependent. Thus, there are striking similarities between this and the collagen-induced arthritis model.
Sujet(s)
Arthrite expérimentale/enzymologie , Arthrite expérimentale/immunologie , Autoantigènes/administration et posologie , Lymphocytes B/immunologie , Glucose 6-phosphate isomerase/administration et posologie , Animaux , Arthrite expérimentale/génétique , Autoanticorps/biosynthèse , Autoanticorps/génétique , Autoanticorps/immunologie , Autoantigènes/génétique , Autoantigènes/immunologie , Lymphocytes B/anatomopathologie , Relation dose-réponse (immunologie) , Femelle , Prédisposition génétique à une maladie , Glucose 6-phosphate isomerase/génétique , Glucose 6-phosphate isomerase/immunologie , Immunisation/méthodes , Inflammation/anatomopathologie , Mâle , Souris , Lignées consanguines de sourisRÉSUMÉ
Rheumatoid arthritis is a chronic inflammatory disease primarily affecting the joints. The search for arthritogenic autoantigens that trigger autoimmune responses in rheumatoid arthritis has largely focused on cartilage- or joint-specific Ags. In this study, we show that immunization with the ubiquitously expressed glycolytic enzyme glucose-6-phosphate isomerase (G6PI) induces severe peripheral symmetric polyarthritis in normal mice. In genetically unaltered mice, T cells are indispensable for both the induction and the effector phase of G6PI-induced arthritis. Arthritis is cured by depletion of CD4(+) cells. In contrast, Abs and FcgammaR(+) effector cells are necessary but not sufficient for G6PI-induced arthritis in genetically unaltered mice. Thus, the complex pathogenesis of G6PI-induced arthritis in normal mice differs strongly from the spontaneously occurring arthritis in the transgenic K/B x N model where Abs against G6PI alone suffice to induce the disease. G6PI-induced arthritis demonstrates for the first time the induction of organ-specific disease by systemic autoimmunity in genetically unaltered mice. Both the induction and effector phase of arthritis induced by a systemic autoimmune response can be dissected and preventive and therapeutic strategies evaluated in this model.